Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Flow Cytometry.
Gascue A, Merino J, Paiva B. Gascue A, et al. Among authors: paiva b. Hematol Oncol Clin North Am. 2018 Oct;32(5):765-775. doi: 10.1016/j.hoc.2018.05.004. Epub 2018 Jul 31. Hematol Oncol Clin North Am. 2018. PMID: 30190016 Review.
Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
García-Sanz R, Ocio E, Caballero A, Magalhães RJ, Alonso J, López-Anglada L, Villaescusa T, Puig N, Hernández JM, Fernández-Calvo J, Aguilar A, Martín A, López R, Paiva B, Orfao A, Vidriales B, San-Miguel JF, Del Carpio D. García-Sanz R, et al. Among authors: paiva b. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):168-71. doi: 10.3816/CLML.2011.n.040. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21856552
Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.
Paiva B, Montes MC, García-Sanz R, Ocio EM, Alonso J, de Las Heras N, Escalante F, Cuello R, de Coca AG, Galende J, Hernández J, Sierra M, Martin A, Pardal E, Bárez A, Alonso J, Suarez L, González-López TJ, Perez JJ, Orfao A, Vidríales MB, San Miguel JF. Paiva B, et al. Leukemia. 2014 Jan;28(1):166-73. doi: 10.1038/leu.2013.124. Epub 2013 Apr 22. Leukemia. 2014. PMID: 23604227
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
Paiva B, Chandia M, Puig N, Vidriales MB, Perez JJ, Lopez-Corral L, Ocio EM, Garcia-Sanz R, Gutierrez NC, Jimenez-Ubieto A, Lahuerta JJ, Mateos MV, San Miguel JF. Paiva B, et al. Haematologica. 2015 Feb;100(2):e53-5. doi: 10.3324/haematol.2014.115162. Epub 2014 Nov 7. Haematologica. 2015. PMID: 25381128 Free PMC article. No abstract available.
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.
Vidriales MB, Pérez-López E, Pegenaute C, Castellanos M, Pérez JJ, Chandía M, Díaz-Mediavilla J, Rayón C, de Las Heras N, Fernández-Abellán P, Cabezudo M, de Coca AG, Alonso JM, Olivier C, Hernández-Rivas JM, Montesinos P, Fernández R, García-Suárez J, García M, Sayas MJ, Paiva B, González M, Orfao A, San Miguel JF; PETHEMA Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. Vidriales MB, et al. Among authors: paiva b. Leuk Res. 2016 Jan;40:1-9. doi: 10.1016/j.leukres.2015.10.002. Epub 2015 Oct 22. Leuk Res. 2016. PMID: 26598032
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán JJ, Vidriales MB, García-Sanz R, Jimenez C, González M, Martínez-López J, Corral-Mateos A, Grigore GE, Fluxá R, Pontes R, Caetano J, Sedek L, Del Cañizo MC, Bladé J, Lahuerta JJ, Aguilar C, Bárez A, García-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, van Dongen JJM, Orfao A. Flores-Montero J, et al. Among authors: paiva b. Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20. Leukemia. 2017. PMID: 28104919 Free PMC article.
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD. Seckinger A, et al. Among authors: paiva b. Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2. Cancer Cell. 2017. PMID: 28262554 Free article.
352 results